A systematic review on recurrent respiratory papillomatosis: clinical effect and duration of benefit of different treatment modalities
AbstractThe aim of this study is to compare different modalities used for the treatment of recurrent respiratory papillomatosis (RRP) in adults and children in terms of their clinical effect and the duration of benefit. Systematic review of papers was written in the English language and published between 1977 and 2007. Outcomes are number of patients with a clinical response and length of time the response lasted for. We found 28 useful studies. There were 1,045 subjects, 416 children and 339 adults who underwent different treatments for RRP between 1976 and 2007. The methods used consisted of cidofovir, interferon, surgical excision, indole-3-carbinol, acyclovir, mumps vaccine, and photodynamic therapy. 62.5% of patients had a complete response on cidofovir (11 studies), 45.14% on interferon (8 studies), 33.33% on I3C (2 studies), 44.36% after surgery (5 studies), 77.55% after the mumps vaccine (1 study), 100% on acyclovir (1 study), and 9.09% after photodynamic therapy (1 study). The effect of different modalities lasted between 9 and 27 months. In conclusion, it is impossible to reach any reliable conclusions as to which method is the most durable and effective. There is a great need for randomised control multicentre trials on the treatment of RRP, so that reliable results can be produced.
FULL TEXT: 168
PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.
Copyright (c) 2011 Elina Kiverniti, Nick Sevdalis, Anastasia Rachmanidou-Doran
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.